An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivoHuiping Shuai, Hin Chu, Jie Zhou et al.|Nature Communications|2025Cited by 8
Pathogenicity, virological features, and immune evasion of SARS-CoV-2 JN.1-derived variants including JN.1.7, KP.2, KP.3, and KP.3.1.1Jialu Shi, Hin Chu, Jie Zhou et al.|Nature Communications|2025Cited by 6
An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivoHin Chu, Shengyong Yang, Shuofeng Yuan et al.|Research Square|2024Cited by 1
Author Correction: An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivoHuiping Shuai, Hin Chu, Jie Zhou et al.|Nature Communications|2025Cited by 0